1-Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance.
Alzheimer Disease
/ metabolism
Insulin Resistance
Humans
1-Deoxynojirimycin
/ pharmacology
Neurons
/ metabolism
Cell Line, Tumor
Amyloid beta-Peptides
/ metabolism
tau Proteins
/ metabolism
Glucose Transporter Type 3
/ metabolism
Insulin
/ metabolism
Signal Transduction
/ drug effects
Glucose Transporter Type 4
/ metabolism
Glycogen Synthase Kinase 3 beta
/ metabolism
Phosphorylation
/ drug effects
Biomarkers
/ metabolism
1‐deoxynojirimycin
Alzheimer's disease
amyloid
insulin‐degrading enzyme
neuronal insulin signaling
tau
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
revised:
29
05
2024
received:
18
12
2023
accepted:
25
06
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
9
7
2024
Statut:
ppublish
Résumé
Insulin resistance, the hallmark of type 2 diabetes mellitus (T2DM), has emerged as a pathological feature in Alzheimer's disease (AD). Given the shared role of insulin resistance in T2DM and AD, repurposing peripheral insulin sensitizers is a promising strategy to preserve neuronal insulin sensitivity and prevent AD. 1-Deoxynojirimycin (DNJ), a bioactive iminosugar, exhibited insulin-sensitizing effects in metabolic tissues and was detected in brain tissue post-oral intake. However, its impact on brain and neuronal insulin signaling has not been described. Here, we investigated the effect of DNJ treatment on insulin signaling and AD markers in insulin-resistant human SK-N-SH neuroblastoma, a cellular model of neuronal insulin resistance. Our findings show that DNJ increased the expression of insulin signaling genes and the phosphorylation status of key molecules implicated in insulin resistance (Y1146-pIRβ, S473-pAKT, S9-GSK3B) while also elevating the expression of glucose transporters Glut3 and Glut4, resulting in higher glucose uptake upon insulin stimuli. DNJ appeared to mitigate the insulin resistance-driven increase in phosphorylated tau and Aβ
Identifiants
pubmed: 38979931
doi: 10.1096/fj.202302600R
doi:
Substances chimiques
1-Deoxynojirimycin
19130-96-2
Amyloid beta-Peptides
0
tau Proteins
0
Glucose Transporter Type 3
0
Insulin
0
Glucose Transporter Type 4
0
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
SLC2A4 protein, human
0
Biomarkers
0
SLC2A3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23800Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 21J12380
Informations de copyright
© 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Soto M, Cai W, Konishi M, Kahn CR. Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior. Proc Natl Acad Sci USA. 2019;116:6379‐6384.
Arvanitakis Z, Wang HY, Capuano AW, et al. Brain insulin signaling, Alzheimer disease pathology, and cognitive function. Ann Neurol. 2020;88:513‐525.
Leclerc M, Bourassa P, Tremblay C, et al. Cerebrovascular insulin receptors are defective in Alzheimer's disease. Brain. 2022;146:75‐90.
Talbot K, Wang H‐Y, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF‐1 resistance, IRS‐1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316‐1338.
Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF‐1 receptor, insulin receptor and IRS‐1/2 in Alzheimer's disease indicate possible resistance to IGF‐1 and insulin signalling. Neurobiol Aging. 2010;31:224‐243.
Starks EJ, Patrick O'Grady J, Hoscheidt SM, et al. Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOEɛ4 carriers. J Alzheimers Dis. 2015;46:525‐533.
Baki L, Shioi J, Wen P, et al. PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004;23:2586‐2596.
Sen T, Saha P, Jiang T, Sen N. Sulfhydration of AKT triggers tau‐phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease. Proc Natl Acad Sci USA. 2020;117:4418‐4427.
Qiu WQ, Folstein MF. Insulin, insulin‐degrading enzyme and amyloid‐β peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27:190‐198.
Zhao L, Teter B, Morihara T, et al. Insulin‐degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci. 2004;24:11120‐11126.
Molina‐Fernández R, Picón‐Pagès P, Barranco‐Almohalla A, et al. Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta‐peptide. Brain Commun. 2022;4:fcac243.
Kimura T, Nakagawa K, Kubota H, et al. Food‐grade mulberry powder enriched with 1‐Deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem. 2007;55:5869‐5874.
Onose S, Ikeda R, Nakagawa K, et al. Production of the α‐glycosidase inhibitor 1‐deoxynojirimycin from bacillus species. Food Chem. 2013;138:516‐523.
Yamagishi K, Onose S, Takasu S, et al. Lactose increases the production of 1‐deoxynojirimycin in bacillus amyloliquefaciens. Food Sci Technol Res. 2017;23:349‐353.
Thakur K, Zhang Y‐Y, Mocan A, Zhang F, Zhang J‐G, Wei Z‐J. 1‐Deoxynojirimycin, its potential for management of non‐communicable metabolic diseases. Trends Food Sci Technol. 2019;89:88‐99.
Hu X‐Q, Thakur K, Chen G‐H, et al. Metabolic effect of 1‐deoxynojirimycin from mulberry leaves on db/db diabetic mice using liquid chromatography–mass spectrometry based metabolomics. J Agric Food Chem. 2017;65:4658‐4667.
Ren X, Xing Y, He L, et al. Effect of 1‐Deoxynojirimycin on insulin resistance in prediabetic mice based on next‐generation sequencing and intestinal microbiota study. J Ethnopharmacol. 2022;289:115029.
Parida IS, Takasu S, Ito J, et al. Supplementation of bacillus amyloliquefaciens AS385 culture broth powder containing 1‐deoxynojirimycin in a high‐fat diet altered the gene expressions related to lipid metabolism and insulin signaling in mice epididymal white adipose tissue. Food Funct. 2020;11:3926‐3940.
Liu Q, Li X, Li C, Zheng Y, Peng G. 1‐Deoxynojirimycin alleviates insulin resistance via activation of insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice. Molecules. 2015;20:21700‐21714.
Liu Q, Li X, Li C, et al. 1‐Deoxynojirimycin alleviates liver injury and improves hepatic glucose metabolism in db/db mice. Molecules. 2016;21:279.
Takasu S, Parida IS, Ito J, et al. Intestinal absorption and tissue distribution of Aza‐sugars from mulberry leaves and evaluation of their transport by sugar transporters. J Agric Food Chem. 2020;68:6656‐6663.
Parida IS, Takasu S, Ito J, et al. Physiological effects and organ distribution of bacillus amyloliquefaciens AS385 culture broth powder containing 1‐Deoxynojirimycin in C57BL/6J mice. J Nutr Sci Vitaminol (Tokyo). 2019;65:157‐163.
Takasu S, Parida IS, Onose S, et al. Evaluation of the anti‐hyperglycemic effect and safety of microorganism 1‐deoxynojirimycin. PLoS One. 2018;13:e0199057.
Chen GH, Tong JJ, Wang F, et al. Chronic adjunction of 1‐deoxynojirimycin protects from age‐related behavioral and biochemical changes in the SAMP8 mice. Age (Dordr). 2015;37:102.
Chen W, Liang T, Zuo W, et al. Neuroprotective effect of 1‐Deoxynojirimycin on cognitive impairment, β‐amyloid deposition, and neuroinflammation in the SAMP8 mice. Biomed Pharmacother. 2018;106:92‐97.
Noel A, Ingrand S, Barrier L. Anti‐amyloidogenic effects of glycosphingolipid synthesis inhibitors occur independently of ganglioside alterations. Mol Cell Neurosci. 2016;75:63‐70.
Ahuja‐Casarín AI, Merino‐Montiel P, Vega‐Baez JL, et al. Tuning the activity of iminosugars: novel N‐alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. J Enzyme Inhib Med Chem. 2021;36:138‐146.
Evangelista TCS, López Ó, Puerta A, et al. A hybrid of 1‐deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE). J Enzyme Inhib Med Chem. 2022;37:2395‐2402.
Nakagawa K, Ogawa K, Higuchi O, Kimura T, Miyazawa T, Hori M. Determination of iminosugars in mulberry leaves and silkworms using hydrophilic interaction chromatography–tandem mass spectrometry. Anal Biochem. 2010;404:217‐222.
Jantrapirom S, Nimlamool W, Chattipakorn N, et al. Liraglutide suppresses tau hyperphosphorylation, amyloid Beta accumulation through regulating neuronal insulin signaling and BACE‐1 activity. Int J Mol Sci. 2020;21:1725.
Zaulkffali AS, Md Razip NN, Syed Alwi SS, et al. Vitamins D and E stimulate the PI3K‐AKT Signalling pathway in insulin‐resistant SK‐N‐SH neuronal cells. Nutrients. 2019;11:2525.
Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81:471‐483.
Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005;32:486‐510.
Asai A, Nakagawa K, Higuchi O, et al. Effect of mulberry leaf extract with enriched 1‐deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig. 2011;2:318‐323.
Ashrafi G, Wu Z, Farrell RJ, Ryan TA. GLUT4 mobilization supports energetic demands of active synapses. Neuron. 2017;93:606‐615.
Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin‐stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3‐kinase dependent. Brain Res. 2009;1296:35‐45.
Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab. 2008;295:E242‐E253.
Uemura E, Greenlee HW. Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Exp Neurol. 2006;198:48‐53.
Lee SM, Do HJ, Shin MJ, et al. 1‐Deoxynojirimycin isolated from a Bacillus subtilis stimulates adiponectin and GLUT4 expressions in 3T3‐L1 adipocytes. J Microbiol Biotechnol. 2013;23:637‐643.
Li Q, Wang Y, Dai Y, Shen W, Liao S, Zou Y. 1‐Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR‐GlUT4 and ADIPO‐GLUT4 pathways in 3T3‐L1 adipocytes. Mol Biol Rep. 2019;46:6277‐6285.
Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase‐3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990‐6995.
Julien C, Tremblay C, Emond V, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:48‐58.
Hadar A, Milanesi E, Walczak M, et al. SIRT1, miR‐132 and miR‐212 link human longevity to Alzheimer's disease. Sci Rep. 2018;8:8465.
Min SW, Sohn PD, Li Y, et al. SIRT1 deacetylates tau and reduces pathogenic tau spread in a mouse model of tauopathy. J Neurosci. 2018;38:3680‐3688.
Fritzen AM, Lundsgaard AM, Jeppesen JF, et al. Fatty acid type‐specific regulation of SIRT1 does not affect insulin sensitivity in human skeletal muscle. FASEB J. 2019;33:5510‐5519.
Shuang E, Yamamoto K, Sakamoto Y, et al. Intake of mulberry 1‐deoxynojirimycin prevents colorectal cancer in mice. J Clin Biochem Nutr. 2017;61:47‐52.